secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001193125-23-290709
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma stockholders approve all four proposals at 2023 Annual Meeting
--------------------------------------------------------------------------------

- Stockholders elected Edward Smith as director: 1,324,883 for, 54,894 withhold, 496,015 broker non-votes.
- Ratification of independent auditor approved: 1,782,870 for, 57,064 against, 35,856 abstain.
- Advisory vote on executive compensation approved: 1,327,852 for, 47,430 against, 4,493 abstain.
- Amendment to 2020 Equity and Incentive Compensation Plan approved: 1,320,120 for, 56,877 against, 2,778 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523290709/0001193125-23-290709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523290709/d555443d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-290709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer